Cover Image
市場調查報告書

斑塊型乾癬 : 開發平台分析

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 199662
出版日期 內容資訊 英文 294 Pages
訂單完成後即時交付
價格
Back to Top
斑塊型乾癬 : 開發平台分析 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 294 Pages
簡介

所謂斑塊型乾癬是慢性,復發,發炎性的皮膚疾病。斑塊型乾癬的頻率·嚴重度受到抽煙,日光暴露,演算法,及HIV感染等環境要素影響。斑塊型乾癬的症狀有包覆著白銀脫屑的皮膚紅斑,小脫屑,伴隨出血可能性的乾裂皮膚、灼熱感,發癢,刺痛般疼痛,指甲肥厚,凹下或溝狀,關節腫脹,關節硬化,及頭皮產生頭皮屑般脫屑等。斑塊型乾癬主要由皮膚科專門醫生的體檢來診斷,沒有診斷用血液檢驗或實驗室檢驗。

本報告提供斑塊型乾癬的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

斑塊型乾癬;概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

治療藥的開發企業

  • 3SBio Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Avesthagen Limited
  • Avexxin AS
  • BIOCAD
  • Biocon Limited
  • Bionovis SA
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion, Inc.
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Forward Pharma A/S
  • Galectin Therapeutics, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Hetero Drugs Limited
  • Idera Pharmaceuticals, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Kadmon Corporation, LLC
  • Kineta, Inc.
  • Kyowa Hakko Kirin
  • LEO Pharma A/S
  • Lipidor AB
  • Mabion SA
  • Mabtech Limited
  • Maruho
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Promius Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Provectus Biopharmaceuticals, Inc.
  • R-Tech Ueno, Ltd.
  • TetraLogic Pharmaceuticals
  • Therapeutic Proteins International, LLC
  • UCB S.A.
  • Valeant Pharmaceuticals International, Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (betamethasone dipropionate + calcipotriene)
  • (calcipotriene + betamethasone dipropionate)
  • (calcipotriene + betamethasone)
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • AM-001
  • AVX-001
  • betamethasone valerate + maxacalcitol
  • bimekizumab
  • bleselumab
  • brodalumab
  • calcipotriene
  • CC-90005
  • CT-327
  • dalazatide
  • DFD-01
  • DFD-06
  • dimethyl fumarate
  • DLX-105
  • DNX-114
  • DNX-514
  • DRM-02
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • GK-664S
  • GRMD-02
  • GSK-2981278
  • guselkumab
  • IDP-118
  • IDP-122
  • IMO-84001
  • IMP-731
  • infliximab biobetter
  • infliximab biosimilar
  • infliximab biosimilar
  • infliximab biosimilar
  • infliximab biosimilar
  • INV-103
  • KD-025
  • LEO-32731
  • LP-0113
  • M-7040
  • MOL-4239
  • MOL-4249
  • pefcalcitol
  • PF-04965842
  • PF-06700841
  • PH-10
  • piclidenoson
  • RTU-1096
  • SHP-141
  • tofacitinib
  • toreforant tartrate
  • UCB-5857
  • ustekinumab biosimilar

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8559IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline landscape.

Plaque psoriasis is a chronic, relapsing, inflammatory skin disorder. The frequency and intensity of psoriasis is affected by environmental factors such as smoking, sun exposure, alcoholism, and HIV infection. The symptoms of psoriasis include red patchy skin covered with silver scales, small scaling spots; dry cracked skin that may bleed; burning, itching, soreness, thickened, pitted or ridged nails; joint swelling and stiffening, and dandruff-like scaling over the scalp. Psoriasis is primarily diagnosed through an examination of the skin by dermatologist, as there are no blood tests or laboratory tests for a diagnosis of psoriasis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 20, 26, 13, 2, 11, 8 and 1 respectively for Plaque Psoriasis (Psoriasis Vulgaris).

Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Plaque Psoriasis (Psoriasis Vulgaris) Overview
  • Therapeutics Development
  • Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance
  • Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies
  • Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development
  • Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment
  • Drug Profiles
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products
  • Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbbVie Inc, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbGenomics International, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Alteogen Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cell Medica Limited, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cellceutix Corporation, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Eli Lilly and Company, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Exicure, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lupin Limited, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lycera Corp., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by MetrioPharm AG, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by NeuClone Pty Ltd, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sandoz International GmbH, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TheraMAB LLC, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech Inc, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Ziarco Pharma Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..5), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..6), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..7), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top